

December 2, 2016

  
**TOP** ↑  
Industry  
NEWS

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

  
A HEALTHIER WORLD. DELIVERED.**Executive insights. Delivered.**[Learn more](#)

### **1. J&J Makes Play for Swiss Biopharm Firm, Actelion**

J&J and Actelion, an Allschwil, Basel, Switzerland-headquartered biopharmaceutical company, have confirmed that they are in preliminary talks about a potential transaction. For J&J, an acquisition or stake in Actelion would add a rare-disease focus to its pharmaceuticals business. [Read More](#)

### **2. Pfizer Names New Head of Global Supply**

Pfizer has named Kirsten Lund-Jurgensen the new executive vice president and president of Pfizer Global Supply, following the retirement of Anthony Maddaluna. Ms. Lund-Jurgensen, currently vice president, innovative health product portfolio management and consumer operations, will report directly to Ian Read, Pfizer's chairman and CEO. [Read More](#)

### **3. Roche Sells US API Manufacturing Facility to Patheon**

Roche has signed an agreement to sell its 300,000-square-foot active pharmaceutical ingredients (API) manufacturing facility in Florence, South Carolina to Patheon. The acquisition boosts Patheon's capability to provide clinical-scale to commercial-scale API manufacturing. [Read More](#)

### **4. AstraZeneca Partners to Develop Bicyclic Peptides in \$1 Billion-Deal**

Roche has signed an agreement to sell its 300,000-square-foot active pharmaceutical ingredients (API) manufacturing facility in Florence, South Carolina to Patheon. The acquisition boosts Patheon's capability to provide clinical-scale to commercial-scale API manufacturing. [Read More](#)

### **5. Novartis Buys Selexys in \$665-Million Deal**

Novartis acquired Selexys Pharmaceuticals, an Oklahoma City, Oklahoma-based company specializing in hematologic and inflammatory disorders, in a deal worth up to \$665 million. The acquisition boosts Novartis' hematology pipeline with the addition of Selexys' lead sickle cell disease compound, SelG1. [Read More](#)

### **6. Lilly Nixes Regulatory Submission of Alzheimer's Drug**

Eli Lilly and Company is not pursuing regulatory submissions for its biologic drug candidate, solanezumab, for treating mild dementia due to Alzheimer's disease, following disappointing Phase III results. The company has not yet determined its next steps for the program. [Read More](#)

### **7. Amgen, Allergan Seek Approval for Avastin Biosimilar**

Amgen and Allergan have submitted a biologics license application to the FDA for a biosimilar candidate to Avastin (bevacizumab), Roche's anti-cancer biologic. Avastin is Roche's top-selling drug with 2015 sales of CHF 6.68 billion (\$6.56) billion. [Read More](#)

#### 8. [Takeda to Build \\$106-Million Vaccine Manufacturing Plant in Germany](#)

Takeda will invest more than EUR 100 million (\$106 million) to build a new dengue vaccine manufacturing plant in Singen, Germany. The facility is expected to come on line in 2019. [Read More](#)

#### 9. [Catalent Acquires OTC Softgel Company](#)

Catalent has agreed to acquire Accucaps Industries Limited, an Ontario, Canada-based developer and manufacturer of over-the-counter (OTC) pharmaceutical softgels, which will boost Catalent's OTC and prescription pharmaceutical softgel capabilities and capacity. [Read More](#)

#### 10. [Shire Establishes Rare Disease Innovation Hub](#)

Shire is establishing a rare disease innovation hub at its site in Cambridge, Massachusetts. Shire intends to create a cross-disciplinary campus, with teams spanning research, clinical development, medical affairs, business development, and other related functions. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

### About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)